Valneva SE (VALN) EBITDA (2021 - 2026)
Valneva SE (VALN) posted EBITDA of -$21.3 million for Q1 2026, up 15.65% sequentially from -$25.3 million in Q4 2025, and down 3276.1% YoY from $670873.2 in Q1 2025.
Valneva SE (VALN) EBITDA (2021 - 2026) Analysis & Trends
Valneva SE has reported EBITDA for 6 years, with the latest figure at -$21.3 million in Q1 2026.
- Quarterly EBITDA fell 3276.1% year-over-year to -$21.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$89.7 million (down 104.67% YoY) and the FY2025 annual result came in at -$69.1 million, down 294.18% from the prior year.
- EBITDA rose to -$21.3 million in Q1 2026 per VALN's latest filing, from -$25.3 million in the prior quarter.
- Over five years, EBITDA peaked at $38.7 billion in Q4 2022 and troughed at -$38.1 billion in Q3 2022.
- A 5-year average of $14.7 million and a median of -$18.1 million in 2024 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 19080.79% in 2022, down 21259.55% in 2022.
- Over 5 years, EBITDA stood at $38.7 billion in 2022, then slumped by 100.05% to -$20.7 million in 2023, then increased by 18.79% to -$16.8 million in 2024, then slumped by 50.56% to -$25.3 million in 2025, then increased by 15.65% to -$21.3 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$21.3 million, -$25.3 million, and -$37.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | -30.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.44 Mn |
| Mar 31, 2026 | -21.31 Mn |
| Dec 31, 2025 | -25.26 Mn |
| Sep 30, 2025 | -37.06 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | -631,130.66 |
| Dec 31, 2024 | -16.78 Mn |
| Sep 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | -18.09 Mn |
| Mar 31, 2024 | 79.30 Mn |
| Dec 31, 2023 | -20.66 Mn |
| Sep 30, 2023 | -19.27 Mn |
| Jun 30, 2023 | -17.42 Mn |
| Mar 31, 2023 | -13.20 Mn |
| Dec 31, 2022 | 38.67 Bn |
| Sep 30, 2022 | -38.14 Bn |
| Jun 30, 2022 | -125.49 Mn |
| Mar 31, 2022 | -20.65 Mn |
| Dec 31, 2021 | 201.58 Mn |
| Sep 30, 2021 | -178.58 Mn |